Skip to main content
Top
Published in: Medical Oncology 3/2012

01-09-2012 | Original Paper

Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients

Authors: Mahdieh Salimi, Hossein Mozdarani, Keivan Majidzadeh

Published in: Medical Oncology | Issue 3/2012

Login to get access

Abstract

ATM protein kinase plays a critical role in maintaining genome integrity by activating a biochemical chain reaction that in turn leads to cell cycle checkpoint activation and repair of DNA damage. Cyclin D1 acts in regulating the G1 phase of the cell cycle. Experimental and clinical studies suggest them to be involved in transformation and tumour progression. To elucidate the role of ATM and cyclin D1 expression in sporadic breast cancer, we investigated the possible link between their RNA expression levels in ductal carcinoma and normal adjacent versus normal breast tissues measured by Taqman real-time PCR in 119 breast tissues. Results showed that cyclin D1 over-expressed in 51.4% of breast tumours, whereas ATM expression was down regulated in 55% of breast tumours compared to both normal adjacent and normal controls (P ≤ 0.01). Cyclin D1 expression in adjacent normal and normal tissues was not significantly differed, whereas ATM expression in normal adjacent was lower than normal control (P ≤ 0.01). Over-expression of cyclin D1 correlated with ER+ and/or PR+ (oestrogen/progesterone receptor) status, whereas it mostly under-expressed in HER2+ (human epidermal growth factor 2) tumours. ATM under-expression was more observed in triple-negative tumours (ER, PR and HER2). Our results indicated that reduced expression of the ATM and aberrant cyclin D1 expressions may contribute to the development and/or malignant progression of breast carcinomas also the latter could be involved in the regulation of hormone sensitivity associated with ER and PR.
Literature
1.
go back to reference Finnish Cancer Registry. Cancer in Finland 2004 and 2005. Cancer statistics of the national research and development centre for welfare and health. Cancer Society of Finland Publication No. 72. Helsinki; 2007. Finnish Cancer Registry. Cancer in Finland 2004 and 2005. Cancer statistics of the national research and development centre for welfare and health. Cancer Society of Finland Publication No. 72. Helsinki; 2007.
3.
go back to reference Lin Y, et al. Active smoking, passive smoking and breast cancer risk: findings from the Japan collaborative cohort study for evaluation of cancer risk. J Epidemiol. 2008;18:77–83.PubMedCrossRef Lin Y, et al. Active smoking, passive smoking and breast cancer risk: findings from the Japan collaborative cohort study for evaluation of cancer risk. J Epidemiol. 2008;18:77–83.PubMedCrossRef
4.
5.
go back to reference Ministry of Health and Medical Education. Iranian annual national cancer registration report 2005–2006. Ministry of Health and Medical Education, Office of Deputy Minister for Health, Center for Disease Control and Prevention, Cancer Office: Tehran, Iran; 2007. Ministry of Health and Medical Education. Iranian annual national cancer registration report 2005–2006. Ministry of Health and Medical Education, Office of Deputy Minister for Health, Center for Disease Control and Prevention, Cancer Office: Tehran, Iran; 2007.
6.
go back to reference Behjati F, et al. Prognnostic value of chromosome 1 and 8 copy number in invasive ductal breast carcinoma among Iranian woman: an interphase FISH analysis. Pathol Oncol Res. 2005;11:157–63.PubMedCrossRef Behjati F, et al. Prognnostic value of chromosome 1 and 8 copy number in invasive ductal breast carcinoma among Iranian woman: an interphase FISH analysis. Pathol Oncol Res. 2005;11:157–63.PubMedCrossRef
7.
go back to reference Najafi M, Ebrahimi M, Kaviani A, Hashemi E, Montazeri A. Breast conserving surgery versus mastectomy: cancer practice by general surgeons in Iran. BMC cancer. 2005;5:35–39.PubMedCrossRef Najafi M, Ebrahimi M, Kaviani A, Hashemi E, Montazeri A. Breast conserving surgery versus mastectomy: cancer practice by general surgeons in Iran. BMC cancer. 2005;5:35–39.PubMedCrossRef
8.
go back to reference Peters MG, et al. Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer. Oncol Rep. 2004;12:1143–50.PubMed Peters MG, et al. Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer. Oncol Rep. 2004;12:1143–50.PubMed
9.
go back to reference Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66.PubMedCrossRef Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66.PubMedCrossRef
10.
11.
go back to reference Sherr CJ. Cell cycle control and cancer. Harvey Lect. 2000;96:73–92.PubMed Sherr CJ. Cell cycle control and cancer. Harvey Lect. 2000;96:73–92.PubMed
12.
go back to reference Neuma E, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol. 1997;17:5338–47. Neuma E, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol. 1997;17:5338–47.
13.
go back to reference Zwijsen RM, et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997;88:405–15.PubMedCrossRef Zwijsen RM, et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997;88:405–15.PubMedCrossRef
14.
go back to reference Petre CE, Wetherill YB, Danielsen M, Knudsen KE. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem. 2002;277:2207–15.PubMedCrossRef Petre CE, Wetherill YB, Danielsen M, Knudsen KE. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem. 2002;277:2207–15.PubMedCrossRef
15.
go back to reference Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell. 2006;9:13–22.PubMedCrossRef Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell. 2006;9:13–22.PubMedCrossRef
16.
go back to reference Poikonen P, et al. Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer. Br J Cancer. 2005;93:515–9.PubMedCrossRef Poikonen P, et al. Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer. Br J Cancer. 2005;93:515–9.PubMedCrossRef
17.
go back to reference Keyomarsi K, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347:1566–75.PubMedCrossRef Keyomarsi K, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347:1566–75.PubMedCrossRef
18.
go back to reference Suzuki T, et al. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci. 2007;98:644–51.PubMedCrossRef Suzuki T, et al. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci. 2007;98:644–51.PubMedCrossRef
19.
go back to reference Berns E et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene (Amst.). 1995; 159:11–18. Berns E et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene (Amst.). 1995; 159:11–18.
20.
go back to reference Lee A, et al. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast. Jpn J Clin Oncol. 2007;37:708–14.PubMedCrossRef Lee A, et al. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast. Jpn J Clin Oncol. 2007;37:708–14.PubMedCrossRef
21.
go back to reference Cho EY, Choi YL, Han JJ, Kim KM, Oh YL. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Pathol Int. 2008;58:17–25.PubMedCrossRef Cho EY, Choi YL, Han JJ, Kim KM, Oh YL. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Pathol Int. 2008;58:17–25.PubMedCrossRef
22.
go back to reference Aaltonen K, et al. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2008;113:75–82.PubMedCrossRef Aaltonen K, et al. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2008;113:75–82.PubMedCrossRef
23.
go back to reference Stoppa-Lyonnet D, et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 1998;91:3920–6.PubMed Stoppa-Lyonnet D, et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 1998;91:3920–6.PubMed
24.
go back to reference Stankovic T, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet. 1999;353:26–9.PubMedCrossRef Stankovic T, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet. 1999;353:26–9.PubMedCrossRef
25.
go back to reference Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Canc Inst. 2000; 92:10. Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Canc Inst. 2000; 92:10.
26.
go back to reference Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔCT) method. Methods. 2001;25:402–8.PubMedCrossRef Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔCT) method. Methods. 2001;25:402–8.PubMedCrossRef
27.
go back to reference Courjal F, et al. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer. 1996;69:247–53.PubMedCrossRef Courjal F, et al. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer. 1996;69:247–53.PubMedCrossRef
28.
go back to reference Hosokawa Y, Arnold A. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosome Cancer. 1998;1:66–71.CrossRef Hosokawa Y, Arnold A. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosome Cancer. 1998;1:66–71.CrossRef
29.
30.
go back to reference Kenny FS, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res. 1999;5:2069–76.PubMed Kenny FS, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res. 1999;5:2069–76.PubMed
31.
go back to reference Bièche I, Olivi M, Noguès C, Vidaud M, Lidereau R. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer. 2002;86:580–6.PubMedCrossRef Bièche I, Olivi M, Noguès C, Vidaud M, Lidereau R. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer. 2002;86:580–6.PubMedCrossRef
32.
go back to reference Bärlund M, Kuukasjärvi T, Syrjäkoski K, Auvinen A, Kallioniemi A. Frequent amplification and overexpression of CCND1 in male breast cancer. Int J Cancer. 2004;111:968–71.PubMedCrossRef Bärlund M, Kuukasjärvi T, Syrjäkoski K, Auvinen A, Kallioniemi A. Frequent amplification and overexpression of CCND1 in male breast cancer. Int J Cancer. 2004;111:968–71.PubMedCrossRef
33.
go back to reference Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 2004;9:95–104.PubMedCrossRef Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 2004;9:95–104.PubMedCrossRef
34.
go back to reference Bienvenu F, et al. Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature. 2010;463:374–8.PubMedCrossRef Bienvenu F, et al. Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature. 2010;463:374–8.PubMedCrossRef
35.
go back to reference Groshong SD, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol. 1997;11:1593–607.PubMedCrossRef Groshong SD, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol. 1997;11:1593–607.PubMedCrossRef
36.
go back to reference Wilcken NR, Prall OW, Musgrove EA, Sutherland RL. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res. 1997;3:849–54.PubMed Wilcken NR, Prall OW, Musgrove EA, Sutherland RL. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res. 1997;3:849–54.PubMed
37.
go back to reference Yang C, et al. Cyclin D1 enhances the response to estrogen and progesterone by regulating progesterone receptor expression. Mol Cell Biol. 2010;30:3111–25.PubMedCrossRef Yang C, et al. Cyclin D1 enhances the response to estrogen and progesterone by regulating progesterone receptor expression. Mol Cell Biol. 2010;30:3111–25.PubMedCrossRef
38.
go back to reference Takano Y, et al. Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity. J Cancer Res Clin Oncol. 1999;12:505–12.CrossRef Takano Y, et al. Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity. J Cancer Res Clin Oncol. 1999;12:505–12.CrossRef
39.
go back to reference Spyratos F, et al. CCND1 mRNA overexpression is highly related to estrogen receptor positivity but not to proliferative markers in primary breast cancer. Int J Biol Markers. 2000;15:210–4.PubMed Spyratos F, et al. CCND1 mRNA overexpression is highly related to estrogen receptor positivity but not to proliferative markers in primary breast cancer. Int J Biol Markers. 2000;15:210–4.PubMed
40.
go back to reference Utsumi T, et al. Correlation of cyclin D1 mRNA levels with clinico-pathological parameters and clinical outcome in human breast carcinomas. Int J Cancer. 2000;89:39–43.PubMedCrossRef Utsumi T, et al. Correlation of cyclin D1 mRNA levels with clinico-pathological parameters and clinical outcome in human breast carcinomas. Int J Cancer. 2000;89:39–43.PubMedCrossRef
41.
go back to reference Musgrove EA, Hui R, Sweeney KJ, Watts CK, Sutherland RL. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 1996;1:153–62.PubMedCrossRef Musgrove EA, Hui R, Sweeney KJ, Watts CK, Sutherland RL. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 1996;1:153–62.PubMedCrossRef
42.
go back to reference Umekita Y, Ohi Y, Sagara Y, Yoshida H. Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer. 2002;98:415–8.PubMedCrossRef Umekita Y, Ohi Y, Sagara Y, Yoshida H. Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer. 2002;98:415–8.PubMedCrossRef
43.
go back to reference Hwang TS, Han HS, Hong YC, Lee HJ, Paik NS. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int. 2003;53:74–80.PubMedCrossRef Hwang TS, Han HS, Hong YC, Lee HJ, Paik NS. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int. 2003;53:74–80.PubMedCrossRef
44.
go back to reference Boström P et al. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BioMed Central BMC Res Notes. 2009; 2:140. Boström P et al. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BioMed Central BMC Res Notes. 2009; 2:140.
45.
go back to reference Kairouz R, et al. ATM protein synthesis patterns in sporadic breast cancer. Mol Pathol. 1999;52:252–6.PubMedCrossRef Kairouz R, et al. ATM protein synthesis patterns in sporadic breast cancer. Mol Pathol. 1999;52:252–6.PubMedCrossRef
46.
go back to reference Angèle S, et al. Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas. Clin Cancer Res. 2000;6:3536–44.PubMed Angèle S, et al. Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas. Clin Cancer Res. 2000;6:3536–44.PubMed
47.
go back to reference Angèle S, Treillex I, Taniere P, Bremond A, Hall J. Altered expression of DNA double strand break detection and repair proteins in breast carcinomas. Histopathology. 2003;43:347–53.PubMedCrossRef Angèle S, Treillex I, Taniere P, Bremond A, Hall J. Altered expression of DNA double strand break detection and repair proteins in breast carcinomas. Histopathology. 2003;43:347–53.PubMedCrossRef
48.
go back to reference Ding SL, et al. Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade. Br J Cancer. 2004;90:1995–2001.PubMedCrossRef Ding SL, et al. Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade. Br J Cancer. 2004;90:1995–2001.PubMedCrossRef
49.
go back to reference Honrado E, et al. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol. 2005;23:7503–11.PubMedCrossRef Honrado E, et al. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol. 2005;23:7503–11.PubMedCrossRef
50.
go back to reference Cuatrecasas M, et al. ATM gene expression is assocaiated with differentiation and angiogenesis in infiltrating breast carcinomas. Histol Histopathol. 2006;21:149–56.PubMed Cuatrecasas M, et al. ATM gene expression is assocaiated with differentiation and angiogenesis in infiltrating breast carcinomas. Histol Histopathol. 2006;21:149–56.PubMed
51.
go back to reference Ye C, et al. Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival. Cancer. 2007;109:1729–35.PubMedCrossRef Ye C, et al. Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival. Cancer. 2007;109:1729–35.PubMedCrossRef
52.
go back to reference Agrawal A, Murphy RF, Agrawal DK. DNA methylation in breast and colorectal cancers. Mod Pathol. 2007;20:711–21.PubMedCrossRef Agrawal A, Murphy RF, Agrawal DK. DNA methylation in breast and colorectal cancers. Mod Pathol. 2007;20:711–21.PubMedCrossRef
53.
go back to reference Dworkin AM, Huang Tim H-M, Toland AE. Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol. 2009;19:165–71.PubMedCrossRef Dworkin AM, Huang Tim H-M, Toland AE. Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol. 2009;19:165–71.PubMedCrossRef
54.
go back to reference Vo QN, et al. The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene. 2004;23:9432–7.PubMedCrossRef Vo QN, et al. The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene. 2004;23:9432–7.PubMedCrossRef
55.
go back to reference Kontorovich T, Cohen Y, Nir U, Friedman E. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Res Treat. 2009;116:195–200.PubMedCrossRef Kontorovich T, Cohen Y, Nir U, Friedman E. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Res Treat. 2009;116:195–200.PubMedCrossRef
56.
go back to reference Treilleux I, et al. The molecular causes of low ATM protein expression in breast carcinoma; promoter methylation and levels of the catalytic subunit of DNA-dependent protein kinase. Histopathology. 2007;51:63–9.PubMedCrossRef Treilleux I, et al. The molecular causes of low ATM protein expression in breast carcinoma; promoter methylation and levels of the catalytic subunit of DNA-dependent protein kinase. Histopathology. 2007;51:63–9.PubMedCrossRef
57.
go back to reference Tommiska J, et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene. 2008;27:2501–6.PubMedCrossRef Tommiska J, et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene. 2008;27:2501–6.PubMedCrossRef
58.
go back to reference Jeggo PA, Carr AM, Lehmann AR. Splitting the ATM: distinct repair and checkpoint defects in ataxia-telangiectasia. Trends Genet. 1998;14:312–6.PubMedCrossRef Jeggo PA, Carr AM, Lehmann AR. Splitting the ATM: distinct repair and checkpoint defects in ataxia-telangiectasia. Trends Genet. 1998;14:312–6.PubMedCrossRef
Metadata
Title
Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients
Authors
Mahdieh Salimi
Hossein Mozdarani
Keivan Majidzadeh
Publication date
01-09-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0043-5

Other articles of this Issue 3/2012

Medical Oncology 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.